Planning and Executing Response-Adaptive Learn-Phase Clinical Trials: 1. The Process
暂无分享,去创建一个
Amarnath Sharma | Kathy Reinold | Michael Krams | Vladimir Dragalin | Daniel D. Burns | Parvin Fardipour | Inna Perevozskaya | Gary Littman | Tom Parke | S. Krishna Padmanabhan
[1] P. Gallo. Confidentiality and Trial Integrity Issues for Adaptive Designs , 2006 .
[2] J M Lachin,et al. The use of response-adaptive designs in clinical trials. , 1993, Controlled clinical trials.
[3] Donald A. Berry,et al. Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development , 2009 .
[4] Andrew P Grieve,et al. ASTIN: a Bayesian adaptive dose–response trial in acute stroke , 2005, Clinical trials.
[5] Ian C Marschner,et al. Interim analysis of continuous long-term endpoints in clinical trials with longitudinal outcomes. , 2003, Statistics in medicine.
[6] I. Marschner,et al. Interim monitoring of clinical trials based on long-term binary endpoints. , 2001, Statistics in medicine.
[7] Amarnath Sharma,et al. Planning and Executing Response-Adaptive Learn-Phase Clinical Trials: 2. Case Studies , 2009 .
[8] M. Krams,et al. Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials , 2007, Journal of biopharmaceutical statistics.
[9] Paul Gallo,et al. Adaptive Dose-Response Studies , 2006 .
[10] Michael Krams,et al. Implementing Adaptive Designs: Logistical and Operational Considerations , 2006 .
[11] V. Fedorov,et al. Adaptive designs for dose-finding based on efficacy–toxicity response , 2006 .